Amgen (NASDAQ:AMGN – Get Free Report) had its target price raised by Bank of America from $256.00 to $275.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “underperform” ...

Bank of America CEO Brian Moynihan discusses the current ... rosemary and saffron act as drugs against cardiovascular disease 'Medieval' King Arthur site is 4,000 years older than we thought ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock ...

“If we get a strong disease-modifying drug and very positive ... Late-stage trial results are expected in the second half of the year. Bank of America analysts including Sachin Jain see ...

and early-stage candidate VX-407 for autosomal dominant polycystic kidney disease. Bank of America analysts said in a research note that the deal “adds strategic value and further bolsters ...

Fourpath Capital Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 20.0% in ...

The underwriting syndicate is led by Goldman Sachs, Bank of America Securities ... the continued development of liver and cardiometablic disease-fighting drug pegozafermin, and manufacturing ...

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy ... The promising Phase 2 data for duvakitug in Crohn’s disease presents a significant de-risked market opportunity ...